Tech Company Financing Transactions

Q32 Bio Funding Round

Abingworth, Acorn Bioventures and Agent Capital participated in a $42 million funding round for Q32 Bio. The round was announced on 3/25/2024.

Transaction Overview

Company Name
Announced On
3/25/2024
Transaction Type
Venture Equity
Amount
$42,000,000
Round
Undisclosed
Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Bdwy. 11th Floor
Cambridge, MA 02142
USA
Phone
Undisclosed
Email Address
Overview
Q32 Bio is a biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems, to re-balance immunity in severe autoimmune and inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7R pathway and complement system, address immune dysregulation to help patients take back control of their lives.
Profile
Q32 Bio LinkedIn Company Profile
Social Media
Q32 Bio Company Twitter Account
Company News
Q32 Bio News
Facebook
Q32 Bio on Facebook
YouTube
Q32 Bio on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Michael Broxson
  Michael Broxson LinkedIn Profile  Michael Broxson Twitter Account  Michael Broxson News  Michael Broxson on Facebook
Chief Scientific Officer
Shelia Violette
  Shelia Violette LinkedIn Profile  Shelia Violette Twitter Account  Shelia Violette News  Shelia Violette on Facebook
Vice President
Susan Kalled
  Susan Kalled LinkedIn Profile  Susan Kalled Twitter Account  Susan Kalled News  Susan Kalled on Facebook
VP - Bus. Development
Maria Marzilli
  Maria Marzilli LinkedIn Profile  Maria Marzilli Twitter Account  Maria Marzilli News  Maria Marzilli on Facebook
VP - Manufacturing
Kathryn Golden
  Kathryn Golden LinkedIn Profile  Kathryn Golden Twitter Account  Kathryn Golden News  Kathryn Golden on Facebook
VP - Operations
Charles Romano
  Charles Romano LinkedIn Profile  Charles Romano Twitter Account  Charles Romano News  Charles Romano on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/25/2024: Eliyan venture capital transaction
Next: 3/25/2024: Edgewood Oncology venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary